Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Oncology ; 92(1): 3-13, 2017.
Article in English | MEDLINE | ID: mdl-27794578

ABSTRACT

Although the efforts to understand the genetic basis of cancer allowed advances in diagnosis and therapy, little is known about other molecular bases. Splicing is a key event in gene expression, controlling the excision of introns decoded inside genes and being responsible for 80% of the proteome amplification through events of alternative splicing. Growing data from the last decade point to deregulation of splicing events as crucial in carcinogenesis and tumor progression. Several alterations in splicing events were observed in cancer, caused by either missexpression of or detrimental mutations in some splicing factors, and appear to be critical in carcinogenesis and key events during tumor progression. Notwithstanding, it is difficult to determine whether it is a cause or consequence of cancer and/or tumorigenesis. Most reviews focus on the generated isoforms of deregulated splicing pattern, while others mainly summarize deregulated splicing factors observed in cancer. In this review, events associated with carcinogenesis and tumor progression mainly, and epithelial-to-mesenchymal transition, which is also implicated in alternative splicing regulation, will be progressively discussed in the light of a new perspective, suggesting that splicing deregulation mediates cell reprogramming in tumor progression by an imperfect shift of the splice program.


Subject(s)
Alternative Splicing , Carcinogenesis/genetics , Neoplasms/genetics , Disease Progression , Humans , Neoplasms/pathology
2.
Sci Rep ; 5: 16877, 2015 Nov 17.
Article in English | MEDLINE | ID: mdl-26574156

ABSTRACT

Chagas disease, which is caused by the parasite Trypanosoma cruzi, is an important cause of cardiomyopathy in Latin America. It is estimated that 10%-30% of all infected individuals will acquire chronic chagasic cardiomyopathy (CCC). The etiology of CCC is multifactorial and involves parasite genotype, host genetic polymorphisms, immune response, signaling pathways and autoimmune progression. Herein we verified the impact of the recombinant form of P21 (rP21), a secreted T. cruzi protein involved in host cell invasion, on progression of inflammatory process in a polyester sponge-induced inflammation model. Results indicated that rP21 can recruit immune cells induce myeloperoxidase and IL-4 production and decrease blood vessels formation compared to controls in vitro and in vivo. In conclusion, T. cruzi P21 may be a potential target for the development of P21 antagonist compounds to treat chagasic cardiomyopathy.


Subject(s)
Cardiomyopathies/etiology , Chagas Disease/pathology , Protozoan Proteins/antagonists & inhibitors , Trypanosoma cruzi/metabolism , Animals , Cardiomyopathies/drug therapy , Cell Adhesion/drug effects , Cell Line , Cell Survival/drug effects , Chagas Disease/drug therapy , Chagas Disease/parasitology , Chemotaxis/drug effects , Cytokines/metabolism , Disease Models, Animal , Inflammation/chemically induced , Inflammation/metabolism , Inflammation/prevention & control , Interleukin-4/metabolism , Leukocytes/cytology , Leukocytes/immunology , Leukocytes/metabolism , Male , Mice , Mice, Inbred C57BL , Neovascularization, Physiologic/drug effects , Peroxidase/metabolism , Protozoan Proteins/genetics , Protozoan Proteins/metabolism , Recombinant Proteins/biosynthesis , Recombinant Proteins/pharmacology , Recombinant Proteins/therapeutic use , Trypanosoma cruzi/isolation & purification
3.
Biotechnol Adv ; 33(8): 1868-77, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26523780

ABSTRACT

This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on animal models and phase I, phase I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful neoadjuvant immunotherapies that can directly target proteins expressed in tumor cells, mainly tumor-associated antigens (TAAs). The most common breast cancer TAA epitopes are derived from MUC1, HER2/neu and CEA proteins. Peptides derived from TAAs could be successfully used to elicit CD8 and CD4 T cell-specific responses. Thus, choosing peptides that adapt to natural variations of human leukocyte antigen (HLA) genes is critical. The most attractive advantage is that the target response is more specific and less toxic than for other therapies and vaccines. Prominent studies on NeuVax - E75 (epitope for HER2/neu and GM-CSF) in breast cancer and DPX-0907 (HLA-A2-TAAs) expressed in breast cancer, ovarian and prostate cancer have shown the efficacy of peptide-based vaccines as neoadjuvant immunotherapy against cancer. Future peptide vaccine strategies, although a challenge to be applied in a broad range of breast cancers, point to the development of degenerate multi-epitope immunogens against multiple targets.


Subject(s)
Antigens, Neoplasm/immunology , Breast Neoplasms/immunology , Peptides/immunology , Vaccines, Subunit/immunology , Breast Neoplasms/prevention & control , CD4-Positive T-Lymphocytes/immunology , Clinical Trials as Topic , Epitopes/immunology , Female , HLA-A2 Antigen/immunology , Humans , Peptides/therapeutic use , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/immunology , Vaccines, Subunit/therapeutic use
4.
Mediators Inflamm ; 2014: 342410, 2014.
Article in English | MEDLINE | ID: mdl-24692848

ABSTRACT

Interleukin-33 (IL-33) is a recently described member of the IL-1 family. IL-33 acts as an alarmin, chemoattractant, and nuclear factor. ST2, a member of the Toll-like receptor/IL-1R superfamily, the receptor of IL-33, triggers a plethora of downstream effectors and leads the activation of NFK-B, leading the expression of several genes. IL-33 and ST2 are expressed in the majority of cell types, and the IL-33/ST2 axis has a role in immune response, bone homeostasis, and osteoclastogenesis. Several studies show opposite roles of IL-33 in osteoclastogenesis and the implication in bone biology. Few works studied the role of IL-33 in periodontal disease, but we hypothesize a possible role of IL-33 in periodontal disease and bone loss.


Subject(s)
Bone and Bones/metabolism , Interleukins/physiology , Periodontal Diseases/metabolism , Periodontal Diseases/physiopathology , Homeostasis , Humans , Immune System , Inflammation , Interleukin-1/metabolism , Interleukin-1 Receptor-Like 1 Protein , Interleukin-33 , Mast Cells/cytology , Necrosis , Osteoclasts/cytology , RANK Ligand/metabolism , Receptors, Cell Surface/metabolism , Signal Transduction
5.
Sci Rep ; 4: 4259, 2014 Mar 04.
Article in English | MEDLINE | ID: mdl-24590372

ABSTRACT

Structural studies of proteins normally require large quantities of pure material that can only be obtained through heterologous expression systems and recombinant technique. In these procedures, large amounts of expressed protein are often found in the insoluble fraction, making protein purification from the soluble fraction inefficient, laborious, and costly. Usually, protein refolding is avoided due to a lack of experimental assays that can validate correct folding and that can compare the conformational population to that of the soluble fraction. Herein, we propose a validation method using simple and rapid 1D (1)H nuclear magnetic resonance (NMR) spectra that can efficiently compare protein samples, including individual information of the environment of each proton in the structure.


Subject(s)
Protozoan Proteins/isolation & purification , Protozoan Proteins/metabolism , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/metabolism , Trypanosoma cruzi , Animals , Chlorocebus aethiops , Escherichia coli/genetics , Escherichia coli/metabolism , Mice , Nuclear Magnetic Resonance, Biomolecular , Protein Denaturation , Protein Refolding , Protozoan Proteins/chemistry , Protozoan Proteins/genetics , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Solubility , Trypanosoma cruzi/genetics , Vero Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...